Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 1, 2012

Diagnostics Deal Weds Metabolon, Lipomics

  • Metabolon said today it has completed its acquisition of Lipomics Technologies for an undisclosed amount.

    Lipomics founder Steven M. Watkins, Ph.D., will join Metabolon’s executive team as chief technology officer as part of the deal, which weds Lipomics’ TrueMass® Profiling lipids technology platform with Metabolon’s metabolomics technology platform for commercial services and diagnostics.

    Metabolon’s lead diagnostic product, Quantose™ IR, is a metabolomics-based insulin resistance diagnostic test for type 2 diabetes. The test measures levels of three novel non-glycemic biomarkers and insulin, with the goal of detecting prediabetes earlier and with greater sensitivity than traditional glycemic markers such as glucose and Hemoglobin A1C.

    “We expect that in 2013 we will be marketing additional diagnostic products aimed at diseases related to obesity and cancer,” Metabolon CEO John Ryals, Ph.D., said in a statement.

    Metabolon will retain its headquarters and laboratories Research Triangle Park, as well as the laboratory facilities of Lipomics at what was its headquarters in Sacramento, CA. The combined company will have more than 140 employees and 450 clients, 2,000 completed commercial projects, and 200 scientific papers either published or under review. Last year alone, Metabolon completed more than 500 client studies and processed over 50,000 samples for customers.

    Financial terms of the transaction were not disclosed.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »